Who is sponsoring NCT04537286?

NCT04537286 is sponsored by Fudan University.

What drugs are being tested in NCT04537286?

Interventions in NCT04537286: nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1).

What condition does NCT04537286 study?

NCT04537286 studies Breast Cancer.

Is NCT04537286 still recruiting?

NCT04537286 is currently status unknown. Last updated 26 February 2024.

Last reviewed 2024-02-26 · How we verify

NCT04537286

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients

Status unknown Phase 2 Last updated 26 February 2024

What this trial tests

Phase 2 trial testing nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1) in Breast Cancer in 90 participants. Status unknown.

Timeline

25 August 2020

Primary endpoint
15 September 2024

15 October 2024

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	25 August 2020
Primary completion	15 September 2024
Estimated completion	15 October 2024
Sites	1 location across China

Drugs / interventions tested

nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1) — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Fudan University

Who can join

Adults 18 to 70, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the efficacy and safety of nab-paclitaxel plus cisplatin plus carilizumab as first-line treatment in patients with metastatic triple-negative breast cancer.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome.
Li L, Zhang F, Liu Z, Fan Z. · · 2023 · cited 73× · PMID 36612317 · DOI 10.3390/cancers15010321
Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review.
Tian H, Ma D, Tan X, Yan W, et al · · 2021 · cited 31× · PMID 34938186 · DOI 10.3389/fphar.2021.770663
Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?
Timon-David E, Perez C, Rodallec A. · · 2022 · cited 2× · PMID 36365144 · DOI 10.3390/pharmaceutics14112326
Development and validation of nomograms of outcomes for first-line platinum-based chemotherapy for metastatic triple-negative breast cancer: patient-level analysis of five prospective clinical trials in China.
Gong C, Li T, Chen Y, Zhang J, et al · · 2025 · PMID 41280131 · DOI 10.1177/17588359251395906

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04537286 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 26 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04537286.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing